#Israel #IceCure Medical #Cryoablation #ProSense® #Maastricht

IceCure Medical Highlights ProSense® Cryoablation at EUSOBI 2026

IceCure Medical Ltd., a leading player in the field of minimally-invasive cryoablation technology, showcased its ProSense® system at the recent European Society of Breast Imaging Annual Scientific Meeting (EUSOBI) held in Maastricht, the Netherlands. This meeting served as a significant platform to present groundbreaking innovations and research related to breast cancer treatments.

Key Highlights from EUSOBI 2026

The event featured several scientific presentations and workshops that spotlighted the effectiveness and clinical applicability of ProSense® cryoablation. With a focus on patient-centric care, the ProSense® system is designed to destroy tumors by freezing, making it a viable alternative to traditional surgical methods.

During the conference, exciting clinical data was presented, showcasing a remarkable objective response rate of 97.5% among 40 patients who underwent combination therapy involving cryoablation and endocrine therapy. Additionally, 91.7% effectiveness was recorded in 24 patients treated solely with cryoablation, proving its efficacy in tackling breast cancer.

Engaging Physician Community

The engagement at EUSOBI was a testament to the growing interest in cryoablation as a treatment for breast cancer. IceCure hosted two informative workshops led by Dr. Lucía Graña-López and Dr. Federica Di Naro, which attracted approximately 70 participants each. These workshops aimed to educate healthcare professionals about the latest advancements in cryoablation and its clinical implications.

Dr. Graña-López presented crucial insights during her session titled "Beyond Biopsy Image-Guided Therapy in Practice," while Dr. Pugliese discussed her findings on local tumor control in elderly patients through cryoablation. Such presentations highlight the importance of integrating innovative technologies in modern cancer care strategies.

Elevating Clinical Practices

IceCure Medical's commitment to advancing breast cancer care was evident in their participation throughout the conference. The inclusion of ProSense® in scientific posters further underscored the collaborative efforts in researching and disseminating knowledge among medical professionals pivotal to improving patient outcomes.

For instance, one of the posters by Dr. Georgiana-Cristiana Camen presented findings on the efficacy and safety of percutaneous cryoablation for breast lesions in Romania. Another poster explored the predictive role of negative Contrast-Enhanced Mammography (CEM) after breast cryoablation, adding depth to the understanding of treatment responses.

A Bright Future Ahead

The positive reception of IceCure's ProSense® system at EUSOBI underscores its increasing relevance in the minimally invasive treatment landscape for breast cancer in Europe. Eyal Shamir, CEO of IceCure Medical, expressed his enthusiasm regarding the significant engagement and interest generated at the event, emphasizing the promising future of cryoablation therapies.

As the medical community continues to explore innovative treatment options, IceCure Medical aims to solidify its role as a leader in minimally-invasive cryoablation therapies globally. Ongoing research and advancements in technology will undoubtedly enhance treatment standards, ensuring that patients have access to safe and effective therapeutic options for breast cancer.

About IceCure Medical

IceCure Medical Ltd. specializes in developing advanced cryoablation therapy systems, enabling tumor destruction through freezing. With a focus on breast, kidney, bone, and lung cancers, the ProSense® system leads the way as the first FDA-cleared device for local treatment of breast cancer among patients aged 70 and older. As they expand their offerings and reach, IceCure remains dedicated to transforming cancer care across the globe.